Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer

  • Technology appraisal guidance
  • TA395
  • Published: 

Lung cancer (non-small-cell, anaplastic lymphoma kinase positive, previously treated) - ceritinib [ID729]: committee papers

Table of Contents

01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the company - Novartis
03 - Addendum to submission from the company
04 - NICE request to the company for clarification on their submission
05 - Company clarification response
06 - Consultee submission - Roy Castle Lung Cancer Foundation
07 - Consultee submission - National Lung Cancer Forum for Nurses
08 - Consultee submission - NCRI-RCP-RCR-ACP-BTOG
09 - Clinical expert personal statement - FORSTER
10 - Clinical expert personal statement - HASWELL
11 - Clinical expert personal statement - THOMAS
12 - Evidence Review Group report prepared by Warwick Evidence
13 - Evidence Review Group report - erratum
14 - Company factual accuracy check of Evidence Review Group report

This page was last updated: 05 October 2015